ArticleEuropean journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology2016
Impact of malignancy on Clostridium difficile infection.
Article in European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 32 citations in OpenAlex.
- Clinical Characteristics and Outcomes Associated with Clostridium Difficile Infection among Hospitalized Colorectal Cancer Patients Receiving Chemotherapy: a Nationwide Retrospective Analysis.Journal of gastrointestinal cancer · 2026Article
- Impact ofJournal of Korean medical science · 2025Article
- Impact of Antibiotic Prophylaxis Duration on the Incidence of Healthcare-Associated Infections in Elective Colorectal Surgery.Antibiotics (Basel, Switzerland) · 2025Article
- Risk factors and outcomes of Clostridioides difficile infection in patients with colorectal cancer: critical perspective in management.Gut pathogens · 2025Review
- Clostridioides difficile recurrence in individuals with and without cancer: a Swedish population-based cohort study.Infection · 2024Article
- Impact of colon cancer on outcomes in hospitalized patients withProceedings (Baylor University. Medical Center) · 2024Article
- The Role of Bezlotoxumab for the Prevention of RecurrentAntibiotics (Basel, Switzerland) · 2022Review
- Outcomes ofEuropean journal of hospital pharmacy : science and practice · 2022Article
- Clinical Impact of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor AssociatedOncoTargets and therapy · 2022Article
- To study the contributing factors and outcomes of Clostridioides difficile infection in patients with solid tumors.Heliyon · 2021Article
- Safety and efficacy of fecal microbiota transplantation to treat and prevent recurrentJournal of Cancer · 2021Article
- Exploratory Evaluation of Bezlotoxumab on Outcomes Associated WithOpen forum infectious diseases · 2020Article
- Risk Factors Associated With RecurrentJournal of clinical medicine research · 2019Article
- Prognosis of Clostridium difficile infection in adult oncohaematological patients: experience from a large prospective observational study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018Observational
- Article
- Bezlotoxumab for the prevention of recurrentAnnals of gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe purpose of this study was to investigate the impact of malignancy and chemotherapy on the clinical and microbiological characteristics of Clostridium difficile infections (CDI).
methodsCDI patients with a history of malignancy within 5 years were defined as the cancer group. The characteristics of the patients were compared according to the presence of malignancy.
resultsOf 580 patients with CDI, 159 (27.4 %) belonged to the cancer group and 421 (72.6 %) to the non-cancer group. More of the patients in the cancer group than those in the non-cancer group had been hospitalized within the prior 2 months (P < 0.001). Leukocytosis was more common in the non-cancer group (P = 0.034), while infection by PCR ribotype 017 strains was more common in the cancer group, with marginal significance (P = 0.07). Recurrence was more frequent in the cancer group (20.4 % vs. 9.5 %, P =0.005) and cancer was an independent risk factor for recurrence of CDI (OR = 2.66, 95 % CI 1.34-5.29, P =0.005). Age also contributed to the recurrence of CDI (OR = 1.03, 95 % CI 1.00-1.06, P =0.026).
conclusionsMalignancy and age are independent risk factors for recurrence of CDI. Cancer patients require careful observation for recurrence after treatment of CDI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.